Graft-versus-host reaction following blood product transfusion.
The observation of graft-versus-host (GVH) reaction after platelet transfusion in a patient with Hodgkin's disease led us to analyze 38 reported cases in the literature, to outline prognostic factors and to characterize patients at risk. Overall mortality was 68 percent. It was higher among children (76 percent) than among adults (62 percent), and among patients with Hodgkin's disease and immune deficiency syndromes (88 percent) than among those with leukemias (23 percent, p less than 0.005). Following blood transfusions from normal donors, mortality was higher (88 percent) than after transfusions from donors with chronic myelocytic leukemia (25 percent, p less than 0.05). Minimal lymphocyte doses necessary to cause GVH reaction are in excess of 10(7)/kg. Adults seem more resistant to homografts than do children, and the host's cellular immune status is of major prognostic importance. Lymphocytes from donors with chronic myelocytic leukemia may be deficient, and after a threshold dose, the number of lymphocytes transfused does not correlate with clinical outcome. Effective prophylactic measures do exist for this complication but satisfactory therapy does not.
D000293:Adolescent; D000328:Adult; D001803:Blood Transfusion / Q000401:mortality; D002648:Child; D002675:Child, Preschool; D005260:Female; D006087:Graft vs Host Reaction; D006689:Hodgkin Disease / Q000150:complications; D006801:Humans; D007154:Immune System Diseases / Q000150:complications; D007223:Infant; D007938:Leukemia / Q000150:complications; D007951:Leukemia, Myeloid / Q000097:blood; D008297:Male; D008875:Middle Aged; D017713:Platelet Transfusion; D011379:Prognosis; D013921:Thrombocytopenia / Q000209:etiology / Q000628:therapy; D065227:Transfusion Reaction